Aptevo Therapeutics Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aptevo reported Q2 2026 cash of $9.8M (matching entire market cap). Mipletamig showed 87% clinical benefit rate and 81% remission rate in 31 frontline AML patients in Phase 1b RAINIER trial; company targets Phase 2 dose selection by year-end 2026 and regulatory interaction in Q1 2027. Non-dilutive $1.5M grant from Andy Hill Cancer Research Endowment funds APVO451 trispecific development. Aptevo entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave made equity investment at closing representing 7.9% stake with potential to reach 19.99%.
Why this rating
Clinical data validates lead program; non-dilutive funding preserves cash runway. Niowave equity investment and 50/50 deal open new therapeutic area. Relative to $9.8M market cap, these are material strategic moves, though company remains pre-revenue biotech with clinical execution risk.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.